Étiquette : anorexie

Cannabis in Cancer Care, D.I. Abrams and M. Guzman, 2015

Cannabis in Cancer Care D.I. Abrams and M. Guzman Clinical Pharmacology & Therapeutics, 2015, 97, (6), 575-586. Doi : 10.1002/cpt.108   Cannabis has been used inmedicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa,mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, themain bioactive cannabinoid in the plant, has been available as a prescriptionmedication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoidsmay [...]

Lire la suite

The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients : Pilot Study, Gil Bar-Sela et al., 2019

The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients : Pilot Study Gil Bar-Sela, Daniela Zalman, Valerya Semenysty and Eyal Ballan Integrative Cancer Therapies, 2019, Volume 18, 1–8 DOI: 10.1177/1534735419881498   Abstract Background : Cancer-related cachexia and anorexia syndrome (CACS) is a common phenomenon in cancer patients. Cannabis has been suggested to stimulate appetite but research on this issue has yielded mixed results. The current study aimed to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients. Methods : The cannabis capsules used in this study contained two fractions of oil-based compounds. The planned treatment was [...]

Lire la suite

Les psychédéliques peuvent-ils traiter l’anorexie et la dépression ?, RESPADD, Actualités des Addictions, n°102, septembre 2019

Les psychédéliques peuvent-ils traiter l'anorexie et la dépression ? RESPADD, Actualités des Addictions, n°102, septembre 2019   Depuis son enfance, Rachael Petersen a vécu avec un sentiment de chagrin inexplicable qu'aucune pharmacothérapie ou psychothérapie n’a pu entièrement atténuer. Aussi, en 2017, elle s'est portée volontaire pour participer à un petit essai clinique à l'Université Johns Hopkins, qui testait la psilocybine, l'ingrédient actif des champignons hallucinogènes, pour le traitement de la dépression chronique. «J'étais tellement déprimée», a récemment déclaré Petersen, 29 ans. «J’ai eu l’impression que le monde m’avait abandonné, que j’avais perdu le droit d’exister sur cette planète. Vraiment, c’était comme si mes [...]

Lire la suite

A Review of Cannabis in Chronic Kidney Disease Symptom Management, Claudia Ho et al., 2019

A Review of Cannabis in Chronic Kidney Disease Symptom Management Claudia Ho, Dan Martinusen, and Clifford Lo2,4,5 Canadian Journal of Kidney Health and Disease, 2019, Volume 6, 1–14 DOI: 10.1177/2054358119828391 journals.sagepub.com/home/cjk Abstract Purpose of Review : Physical and psychological symptom burden in patients with advanced chronic kidney disease (CKD) is significantly debilitating; yet, it is often inadequately treated. Legalization of cannabis in Canada may attract increasing interest from patients for its medical use in refractory symptom management, but its indications and long-term adverse health impacts are poorly established, creating a challenge for clinicians to support its use. In this review, we summarize key clinical studies and [...]

Lire la suite